From Clinical Results to Practice Integration—Essilor® Stellest® Lenses Webinars for Optometrists and Opticians

Webinars to introduce the newly granted FDA market authorized spectacle lens clinically proven to slow childhood myopia progression in children^1,2

Leading the global effort to address the myopia epidemic, EssilorLuxottica made the Essilor® Stellest® lenses available in October for U.S. eye care professionals following its successful international roll-out. To mark the U.S. launch of Essilor® Stellest®, EssilorLuxottica hosted two webinars—one designed for optometrists and one designed for opticians—to introduce the technology and demonstrate how to bring it into practice.

ACCESS TODAY:

Optometrist Webinar: Essilor® Stellest® Lenses: An Innovation for Pediatric Myopia

• Two-year FDA study results with demonstrated proven efficacy in children will be revealed.
• Optometrists ACCESS HERE
• Note: These webinars are hosted on EssilorLuxottica’s Leonardo platform. If you’re new to the platform, you can easily create a free profile right from the home screen.

Optician Webinar: Essilor® Stellest® Lenses: Technology, Fitting and Follow-Up

• Gain knowledge in its technology, fitting process and follow-up care to help ensure long-term success for your patients.
• Opticians ACCESS HERE
• Note: These webinars are hosted on EssilorLuxottica’s Leonardo platform. If you’re new to the platform, you can easily create a free profile right from the home screen.

ABOUT ESSILOR® STELLEST® LENSES

Essilor® Stellest® lenses are the first and only U.S. Food and Drug Administration (FDA) market authorized granted spectacle lenses clinically proven to slow myopia progression in children^1,2.

The effectiveness of the Essilor® Stellest® lens is evidenced by clinical data showing that the lens slowed down myopia progression by 71% on average over two years^1,2.

This follows the product’s earlier recognition with the FDA granting designation as a Breakthrough Device in 2021.

ABOUT MYOPIA

The myopia epidemic is a global health issue, with half the world population estimated to suffer from myopia by 2050³. Childhood myopia is progressing at a fast pace, with an estimated 740 million children affected worldwide by 2050⁴. Higher levels of myopia are frequently associated with severe eye pathologies later in life, hence the need to provide families with solutions not only to correct myopia but also slow its progression. In North America, over 4 in 10 adults³ and 1 in 4 children⁴ aged 6 to 19 are affected by myopia, and studies³ show that this prevalence is accelerating over years.

EssilorLuxottica has been leading research in this field for more than four decades, culminating in the launch of the Essilor® Stellest® lens in key countries across the world. In line with EssilorLuxottica’s efforts to develop and deliver groundbreaking medical care technology to people around the world, the Essilor® Stellest® lens provides eye care professionals with an evidence-backed, reliable solution for helping families address the challenges of myopia.

Discover more about Essilor® Stellest® lenses here.

Read other recent news on Independent Strong here.

References

1. Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
2. Essilor International, data on file (2025)
3. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. doi:10.1016/j.ophtha.2016.01.006
4. Liang J, Pu Y, Chen J, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis. Br J Ophthalmol. 2025;109(3):362-371. Published 2025 Feb 24. doi:10.1136/bjo-2024-325427